Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02361125 · ClinicalTrials.gov registry record · Phase 1
Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate
A Phase 1 study of Fatigue, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT02361125: Completed Phase 1 study of Fatigue, sponsored by M.D. Anderson Cancer Center.
NCT02361125 is a Phase 1 study of Fatigue that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02361125, a Phase 1 study of Fatigue, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to evaluate the effectiveness of ritalin (methylphenidate) taken on an as needed basis for the management of cancer related fatigue. The effects of methylphenidate on pain, mood, and sedation will be evaluated. Researchers will also evaluate the level of fatigue throughout the day and any possible causes of fatigue.
Primary Outcome
Primary endpoint is fatigue as measured on a 10-point scale. An average 2-point reduction in fatigue from before to 2 hours after taking methylphenidate considered a clinical success.
Conditions Studied
Interventions
- DRUG Methylphenidate
- BEHAVIORAL Fatigue Evaluations
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2002-08-01 |
| Est. Completion | 2021-12-28 |
| Phase | Phase 1 |
What the finished NCT02361125 record still lists
NCT02361125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Fatigue appearing as the primary indexed condition, and to 2 interventions - of which Methylphenidate is the first listed.
NCT02361125 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02361125 about?
NCT02361125 is a clinical study titled "Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate". The goal of this clinical research study is to evaluate the effectiveness of ritalin (methylphenidate) taken on an as needed basis for the management of cancer related fatigue. The effects of methylphenidate on pain, mood, and sedation will be evaluated. Researchers will also evaluate the level of f...
What is the current status of trial NCT02361125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2002-08-01. Estimated completion is 2021-12-28.
What conditions does trial NCT02361125 study?
This clinical trial studies the following conditions: Fatigue.
What interventions are being tested in trial NCT02361125?
The interventions under investigation include: Methylphenidate (DRUG), Fatigue Evaluations (BEHAVIORAL).
Who is sponsoring clinical trial NCT02361125?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02361125 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02361125's enrollment target sits among peer trials
31 83rd of 109 higher than 26 of 109 other Fatigue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatigue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus
RECRUITING · Phase 1
-
MitoQ for Fatigue in Multiple Sclerosis (MS)
ACTIVE NOT RECRUITING · Phase 1
-
Acupuncture to Treat Cancer-Related Fatigue in Breast Cancer Patients
COMPLETED · Phase 1
-
A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue
COMPLETED · Phase 1
-
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
COMPLETED · Phase 1
-
Art and Surface Electromyography (EMG)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI